Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Sterols as novel immunomodulatory agents and their use as vaccine adjuvants
US12478671B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12478671-B2 |
| Application number | US-201816641417-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2018 |
| Priority date | Aug 24, 2017 |
| Publication date | Nov 25, 2025 |
| Grant date | Nov 25, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods of using immunomodulatory sterols as vaccine adjuvants. Accordingly, certain embodiments relates to pharmaceutical compositions containing at least one antigen and at least one immunomodulatory sterol; and, methods of inducing an immunomodulatory response in a patient by administering an immunomodulatory-effective amount of at least one immunomodulatory sterol.
First claim
Opening claim text (preview).
What is claimed is: 1 . A pharmaceutical composition comprising an immunomodulatory sterol having the following structure: wherein R 1 is selected from C 1 -C 12 alkyl and C 1 -C 12 alkenyl, and an antigen, wherein the antigen comprises killed, inactivated, attenuated, or modified live bacteria, viruses, or parasites, wherein the immunomodulatory sterol is present in an amount from 0.1 to 100 μg. 2 . The pharmaceutical composition according to claim 1 , wherein R 1 is selected from: 3 . The pharmaceutical composition according to claim 1 , wherein the immunomodulatory sterol has the formula: 4 . The pharmaceutical composition according to claim 1 , wherein the antigen provokes an immune response to Leishmania spp. 5 . The pharmaceutical composition according to claim 1 , wherein the antigen comprises an attenuated strain of Leishmania spp. 6 . The pharmaceutical composition according to claim 1 , wherein the antigen comprises LmCen −/− , Mayrink's vaccine, Convit's vaccine, soluble L. donovani , soluble exogenous antigens of L. major , or L. donovani promastigote soluble antigen. 7 . The pharmaceutical composition according to claim 1 , wherein the immunomodulatory sterol is present in an amount from about 1-25 μg. 8 . A method for vaccinating a subject in need thereof, comprising administering to the subject the composition according to claim 1 . 9 . The method according to claim 8 , wherein R 1 is selected from: 10 . The method according to claim 8 , wherein the immunomodulatory sterol has the formula: 11 . The method according to claim 8 , wherein the antigen provokes an immune response to Leishmania spp. 12 . The method according to claim 8 , wherein the antigen comprises an attenuated strain of Leishmania spp. 13 . The method according to claim 8 , wherein the antigen comprises LmCen −/− , Mayrink's vaccine, Convit's vaccine, soluble L. donovani , soluble exogenous antigens of L. major , or L. donovani promastigote soluble antigen. 14 . The method according to claim 8 , wherein the immunomodulatory sterol is administered in an amount from about 1-25 μg. 15 . The method according to claim 8 , wherein the immunomodulatory sterol and antigen are administered in a single composition. 16 . The method according to claim 8 , wherein the immunomodulatory sterol and antigen are administered in separate compositions.
Assignees
Inventors
Classifications
Organic adjuvants · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Leishmania antigens · CPC title
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12478671B2 cover?
- Disclosed herein are methods of using immunomodulatory sterols as vaccine adjuvants. Accordingly, certain embodiments relates to pharmaceutical compositions containing at least one antigen and at least one immunomodulatory sterol; and, methods of inducing an immunomodulatory response in a patient by administering an immunomodulatory-effective amount of at least one immunomodulatory sterol.
- Who is the assignee on this patent?
- Ohio State Innovation Foundation
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).